Cantor Fitzgerald analyst Sarah James maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of $87.00. The company’s shares closed yesterday at $76.05.
James covers the Healthcare sector, focusing on stocks such as Humana, Centene, and Cigna. According to TipRanks, James has an average return of 11.3% and a 68.34% success rate on recommended stocks.
Currently, the analyst consensus on CVS Health is a Strong Buy with an average price target of $89.43, a 17.59% upside from current levels. In a report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $95.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
CVS market cap is currently $94.92B and has a P/E ratio of 11.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVS Health (CVS) Company Description:
Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.
Read More on CVS:
- A New Cause for Concern: CVS Health Corp Adds a New Corporate Activity and Growth Risk
- CVS Health Corp Earnings Update: Did it Beat Estimate Forecasts?
- CVS Health (NYSE:CVS) Rises after Q4 Earnings Beat
- CVS Health backs FY24 Pharmacy & consumer wellness revenue ‘at least’ $123.4B
- CVS Health backs FY24 Health Services revenue ‘at least’ $169.7B
